RTOG 0436: A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin and Radiation for Patients with Esophageal Cancer who are Treated Without Surgery
The purpose of this study is to determine what effects, good and/or bad, the anti-cancer drug Cetuximab has when added to standard chemotherapy and radiation for specific types and stages of esophageal cancer. Subjects will be randomly assigned to either radiation plus chemotherapy with Cetuximab followed by Cisplatin and Paclitaxel, or radiation plus chemotherapy with only Cisplatin and Paclitaxel. For more information please contact Valerie Fergusson by phone (904-588-1438) or email (email@example.com). (Enrolling in Jacksonville, FL)
Keywordsesophageal cancer, radiation therapy, squamous cell carcinoma, gastric cancer
Principal InvestigatorRomaine Nichols, M.D.
Begin a new search for other research studies
Studies listed on this site have been approved by a UF Institutional Review Board (IRB), which works to ensure the welfare and rights of research participants as required by federal regulations. Study listings are provided by the UF Clinical and Translational Science Institute in collaboration with UF research teams and the UF IRBs.